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Abstract
Rationale: Primary ciliary dyskinesia (PCD) is a rare disease. There are no
available data on disease-specific pediatric patient–reported outcomes.
Objectives: Our objective was to create developmentally appropriate,
health-relatedquality-of-life questionnaires (QOL-PCD) for children (6–12yr)
and adolescents (13–17 yr) with PCD and a parent proxy measure.
Methods: The QOL-PCD was developed using a cross-cultural protocol-
driven approach satisfying both North American and European drug
regulatory agency guidelines. A conceptual framework was generated by
literature review, focus groups (expert clinicians and patients/parents), and
open-ended interviews with children, adolescents, and parents of patients with
PCD.We recruited participants from international research consortiums, PCD
clinics, and patient advocacy groups, aiming for representation of a wide
spectrum of disease severity, sociodemographic status, and ethnicity.
Qualitative interviews were conducted by trained and experienced research
assistants and psychologists. Transcripts were content-analyzed with Atlas.ti/
NVivo to assess saturation of content. A self-completed item relevance survey
was administered to E.U. participants. Qualitative and quantitative data were
used to construct draft instruments. Questionnaires were further refined after
cognitive interviews.
Measurements and Main Results: Focus groups (n = 62 experts; n = 20
patients/parents) and open-ended interviews with patients/parents (n = 69;
34 males; age at diagnosis, 0–15 yr; FEV1, 58–118% predicted) revealed a wide
spectrum of issues unique to this population. Content analysis of transcripts
identified the following domains, depending on age: Respiratory Symptoms,
Physical Functioning, Emotional Functioning, Treatment Burden, Ears and
Hearing, Sinus Symptoms, Social Functioning, Role Functioning, Vitality,
HealthPerceptions, SchoolFunctioning, andEating andWeight.Various items
were retained in questionnaires, based on age and role of respondent: 37, 43,
and 41 items for children, adolescents, and parent proxy, respectively. The item
relevance survey (n = 57) yielded results similar to those of open-ended
interviews. Cognitive testing (n = 47; 20males; age at diagnosis, 0–11 yr; FEV1,
49–124% predicted) confirmed that items and response choices were clear and
understood by respondents, and that all relevant items were included.
Conclusions: The QOL-PCD measures, developed using rigorous, protocol-
driven methods and international collaborations, have demonstrated content
validity and cross-cultural equivalence for implementation in English-speaking
populations. Psychometric testing is underway to determine their measurement
properties for evaluating clinical interventions and informing quality of care.
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Primary ciliary dyskinesia (PCD) is a rare
inherited lung disease affecting motile cilia,
such that mucociliary clearance is impaired.
Individuals with PCD often present with
unexplained respiratory symptoms in the
first few days of life, develop persistent
sinopulmonary symptoms in infancy,
bronchiectasis during childhood, and a
progressive decline in lung function over
time, which can lead to end-stage lung
disease by early to mid-adulthood (1). To
date, no medications to treat PCD have
been approved by regulatory bodies (2),
and a major obstacle to monitoring disease
progression and evaluating new treatments
is the lack of disease-specific outcome
measures (3). Current outcome measures,
such as spirometry, chest computed
tomography, and lung clearance index all
have limitations in terms of their sensitivity
and feasibility for evaluating new therapies
or disease progression (4–7). Importantly,
these physiological measures do not reflect
the impact of the disease on patients’ daily
symptoms or functioning (e.g., physical,
respiratory, social) as required by the
Food and Drug Administration (FDA) (8)
and the European Medicines Agency
(EMA) (9, 10).
Thus, measures are needed to assess
the impact of PCD, from the patient
perspective, on all domains of daily
functioning. Health-related quality-of-life
(HRQoL) measures are valid, reliable, and
informative indices of symptoms and
functioning and sensitive to patient
concerns (11–14). Both the FDA and EMA
support the development and use of
disease-specific patient-reported outcome
measures for evaluation of new medications
and treatments (12). At present there are no
validated HRQoL measures available for
pediatric patients with PCD.
Developing a new patient-reported
outcomes measure requires concept
elicitation from patients, using rigorous
qualitative methods, to achieve content
validity, which is a challenge when patients
are geographically disparate with a rare
disease. Once a measure with content
validity is developed, it can be subjected to
psychometric testing to determine its
measurement properties (reliability,
construct validity, and responsiveness), with
item reduction as needed.
Our goal was to develop harmonized
(North America and Europe) pediatric
PCD-specific HRQoL instruments informed
by guidance from the FDA and EMA (8–10),
to be used as primary or secondary
outcomes in clinical trials. In addition,
because patient-reported outcome
measures demonstrate optimal reliability
and validity when they are specific to
the respondent’s developmental stage (15),
we developed three separate age-
appropriate versions of this instrument:
children (aged 6–12 yr), adolescents (aged
13–17 yr), and parent proxy (for children
aged 6–12 yr). This article reports on the
development process and qualitative
research results for these three instruments.
Some of the results of this research have
been previously reported in the form of an
abstract (16).
Methods
Conceptual Framework and
Study Design
We followed the patient-reported outcomes
measure development process outlined by
the FDA (8) and EMA (10) to design the
study, procedures, and analytic plan
(Figure 1). The study was approved by the
Research Ethics Board at the Hospital for
Sick Children (Toronto, ON, Canada);
the Institutional Review Boards at the
University of North Carolina (Chapel Hill,
NC), Washington University (St. Louis,
MO), and the University of Miami (Miami,
FL); and the National Research Ethics
Service (London, UK) (UK 07/Q1702/109).
Informed consent and assent, as
appropriate, were obtained before
interviews.
Literature Review and Clinician
Focus Groups
First, a systematic literature review was
conducted to identify key symptoms and
effects of PCD on patient functioning.
MEDLINE and EMBASE were searched and
additional references were sought through
citations in reviewed studies. Next, expert
physicians (e.g., pulmonologists,
otolaryngologists), allied health
professionals, and researchers met to
discuss their own perceptions of the impact
of PCD on pediatric patients at the
American Thoracic Society Conference
and European Respiratory Society
Congress. These literature reviews and
discussions led to the development of the
conceptual framework, which guided the
open-ended interviews subsequently
conducted with patients with PCD and
parent caregivers.
Co
nc
ep
tu
al
Fr
am
ew
or
k
El
uc
id
at
io
n
Ite
m
 G
en
er
at
io
n
Co
nf
irm
at
io
n 
of
co
n
te
nt
 v
al
id
ity
QOL-PCD version 1.1
Discussion Guide
Patient/parent Focus Groups (n=20);
Individual Interviews (n=69);
UK Relevance Survey (n= 57)
Content analysis of interview data;
generation of saturation matrices
Generate questionnaire items to
reflect patient/parent terminology
QOL-PCD version 1.2
Cognitive interviews with
patients/parents (n=47)
Analysis of interview data
Clinician Focus Groups
Literature Review
Figure 1. Development process for pediatric health-related quality-of-life measures for primary ciliary
dyskinesia (QOL-PCD).
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Participants with PCD and Setting
English-speaking children with PCD, ages
6–17 years, and parent caregivers, were
recruited from the North American (United
States and Canada) GDMCC (Genetic
Diseases of Mucociliary Clearance
Consortium) sites and European (United
Kingdom and Ireland) BESTCILIA (Better
Experimental Screening and Treatment for
Primary Ciliary Dyskinesia) sites during
periods of clinical stability. Participants in
North America were recruited from a
patient conference sponsored by the North
American PCD Foundation, and patients
with PCD were evaluated at the University
of North Carolina, Washington University,
and the Hospital for Sick Children.
In Europe, participants were recruited
from PCD clinics in the United Kingdom
and Ireland and via an announcement
circulated through the PCD Family Support
Group UK. We used convenience sampling,
but aimed to recruit patients of various
ethnic backgrounds, socioeconomic status,
and disease severity to increase the
representativeness of the sample.
To avoid bias associated with
diagnostic misclassification, criteria for
participation in the open-ended and
cognitive interviews included a confirmed
diagnosis of PCD through the GDMCC or
BESTCILIA specialized PCD research
centers. North American participants were
diagnosed on the basis of a compatible
clinical phenotype plus defect in ciliary
ultrastructure and/or identification of
biallellic disease-causing mutations in one
of the PCD genes (17). UK and Irish
participants had a multidisciplinary
diagnostic decision based on clinical
phenotype, nasal nitric oxide, and
reproducible “hallmark” abnormalities of
ciliary function assessed by high-speed
video analysis and/or assessment of ciliary
ultrastructure by electron microscopy (18).
Item Generation: PCD Patient/Parent
Focus Groups and Individual
Interviews; UK Relevance Survey
We conducted focus groups with children,
adolescents, and parents at a PCD Family
Day sponsored by the North American PCD
Foundation in Buffalo, New York.
Individual, semistructured, open-ended
interviews were then conducted in person
with children and adolescents with PCD and
parent caregivers at multiple sites in North
America and Europe to elicit the effects of
PCD from the patient and parent
perspectives. All interviews were conducted
in North America by A.L.Q., A.A., and other
research assistants, and in the United
Kingdom by L.B. All interviewers were
psychologists, had extensive training and
experience in conducting qualitative
interviews, and had no preexisting
relationships with the study participants.
The framework (interview guide)
underpinning the interviews was
prospectively and jointly (between North
American and European sites) developed
after the expert focus groups and literature
review.
In addition, a postal survey with a list of
potential items generated from the clinician
and patient/parent focus groups was
circulated by the Family Support Group in the
United Kingdom, to rate item relevance and
importance by patients. Participants were
asked to rate each item on a five-point Likert
scale (1, not relevant; 5, highly relevant).
Responses were analyzed according to age
group, examining means and response
distributions for each item for the child,
adolescent, and parent samples.
Content Analysis of Patient/Parent
Interview Data
All interviews were audiotaped and
transcribed for content analysis, using either
Atlas.ti in North America (version 7.0;
Scientific Software Development, Berlin,
Germany) or NVivo in the United Kingdom
(version 8.0; QSR International Pty Ltd,
Doncaster, Victoria, Australia). Thematic
coding was used to identify key symptoms
and psychosocial impacts. These data were
then analyzed for their frequency of
endorsement and level of impact. Saturation
matrices were derived to inform item
generation and to ensure that data
saturation was achieved (i.e., no new themes
arose with new interviewees) (19).
Frequently endorsed items were written
using patient and parent language from the
original transcripts. This ensured that the
items captured the meaning, language level,
and context of their experiences.
Construction of Prototype
Questionnaires
Agreement on item selection and wording
was achieved during multidisciplinary,
multinational conference calls using a
modified Delphi approach (20). We
discussed the specific quotes and saturation
grids from the interviews, and results from
the item relevance survey. Selected items
were written using patient language and
phrases obtained in the qualitative
interviews and were then combined into
scales based on our conceptual framework
(e.g., frequency and severity of respiratory
symptoms, perceptions of treatment
burden). Items were written to ensure
conceptual, cultural, and linguistic
equivalence for North America, Ireland,
and the United Kingdom by researchers
from both regions. We also adhered to both
the FDA and EMA guidances (8–10), and
used a short recall period (i.e., 1 wk).
Cognitive Testing of Prototype
Questionnaires
Cognitive interviews were conducted using a
“think aloud” procedure (21) to evaluate
the clarity, interpretation, relevance,
and comprehensiveness of the draft
instruments. In particular, we asked about
the instructions, interpretation of items,
and use of the rating scales. We also asked
whether any relevant items were missing.
First, participants completed the prototype
questionnaire independently. Next, they
were interviewed either in-person or by
phone (older adolescents, parents), using
specific cognitive probes. All interviews
were audio-recorded and transcribed. The
results were discussed during a series of
teleconferences to determine whether
revisions were required in the formatting,
instructions, items, or rating scale options.
The measures were refined on the basis of
these cognitive interviews and finalized to
form the draft instruments for psychometric
validation.
Results
Conceptual Framework Elucidation
Items were initially generated from the
literature review and focus groups with
expert clinicians treating PCD in North
American (n = 12) and Europe (n = 40).
Clinicians outlined a number of symptoms
related to respiratory and upper airway
pathophysiology, and problems with
chronic otitis media and its sequelae (e.g.,
difficulty hearing, speech delays). A
conceptual framework was then developed
representing key quality-of-life domains:
physical functioning, emotional
functioning, treatment burden, symptoms
(respiratory, sinonasal, ear and hearing),
social functioning, role functioning, eating
ORIGINAL RESEARCH
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and weight, and body image (see Appendix
E1 in the online supplement).
Three separate focus groups at a North
American PCD family day provided
information on the effects of PCD from the
patient and parent perspectives (n = 9,
parents of children under age 12; n = 4
adolescent ages 12 and older; n = 7 parents
of adolescents), which facilitated our
refinement of the conceptual framework. In
addition to symptoms, questions were
asked about how PCD impacted physical
functioning, energy level, and social and
emotional functioning.
Although not as well established as the
cystic fibrosis (CF) treatment regimen, a
number of treatments are currently
prescribed by pulmonologists treating
patients with PCD. Therefore, we asked
several questions about treatment burden.
Social functioning was also affected by
embarrassment about coughing, sputum
production, and ear drainage. All of these
concepts were included in the preliminary
conceptual framework underlying the
patient/parent open-ended interview guide.
Patient/Parent Individual Interviews
and UK Relevance Survey
The North American focus groups were
composed of pediatric patients with PCD
(n = 9), parents of children under age 12 years
(n = 7), and parents of adolescents, ages
12 years and older (n = 4). North American
and European Union participants who
completed the open-ended interviews
included children (n = 20), adolescents
(n = 20), and parents (n = 29), representing
a wide range of disease severity (FEV1,
58–118% predicted) and ethnic groups
(Table 1). Similar numbers of boys and girls
participated, but the majority of parent
respondents were mothers. As expected,
nearly all informants described a chronic
cough and sinonasal symptoms. Selected
patient quotes from the open-ended
interview phase in North America and the
European Union are presented in Table 2.
The UK relevance postal survey
consisted of a list of 78 potential items
for inclusion and was scored for relevance
by 24 children, 9 teenagers, and 24 parent-
proxies.
Item Generation: Content Analysis of
Patient/Parent Interview Data and
Relevance Survey
Content analysis of the transcripts yielded
key items for each of 12 HRQoL domains,
based on the frequency with which they
were mentioned across respondents and the
severity of their impact. Saturation of
content across domains was confirmed
when no new themes emerged (see Table 3
for an example saturation grid for
adolescents). Overall, we achieved
saturation of content by the third to
twentieth interview, depending on the
respondent and specific content area.
Results of the relevance survey (Appendices
E2–E4) overlapped closely with the issues
discussed during open-ended interviews
and the frequency distributions identified
in the saturation matrices.
Development of Prototype
Questionnaire
The first draft measure (QOL-PCD version
1.1) contained the following: (1) child
version (9 scales, 43 items), (2) parent
proxy version (10 scales, 50 items), and (3)
adolescent version (11 scales, 52 items). We
subjected all three measures to the Flesch–
Kincaid Readability Index with the
following results: (1) the child measure for
those 6–12 years of age was at the fourth
grade level (ages 9–10); to increase the
readability and response effort for young
children, we developed a pictorial version
of the items, presented and “read” to the
child by computer (Figure 2); (2) the
adolescent version (13–17 yr) had a
readability index of sixth grade (6.6), which
is about 11 years; and (3) the parent version
was at a 6.5 grade reading level.
Cognitive Testing of Prototype
Questionnaire
Cognitive interviews were conducted with
14 children, 16 adolescents, and 17 parents
(Table 2). Review of these transcripts
indicated that all respondents found the
items clear and comprehensive, with rating
scale options that were easy to use.
However, some items were not viewed as
relevant or important (e.g., “you thought
you were too thin”; Body Image). These
items were removed from each prototype
questionnaire, based on patient/parent
input after the cognitive testing phase
(Table 4). Specifically, six items were
removed from the child questionnaire; nine
items were removed from the parent proxy
questionnaire; and nine items were
removed from the adolescent questionnaire.
Because of lack of endorsement, items
assessing domains such as body image,
eating and weight were removed from the
child and adolescent instruments (e.g., “I
think I look different from others my age,”
“I think I am smaller than others my age,”
“I have to push myself to eat,” and “Have
you had trouble gaining weight?”). Thus,
the final prototype instruments (QOL-PCD
version 1.2) contained the following
numbers of items: (1) child version (37
items), (2) parent proxy version (41 items),
and (3) adolescent version (43 items)
(Table 5).
Discussion
The primary goal of this study was to
develop the first HRQoL instruments for
pediatric patients with PCD and parent
caregivers, following guidelines on the
development of patient-reported outcome
measures established by the FDA and EMA.
Using data from both North America and
the United Kingdom, we conducted an
expert clinician panel, focus groups, and
individual open-ended interviews, followed
by item generation and cognitive testing.
This process yielded separate instruments
for school-age children, adolescents, and
parents. Similar processes were used to
develop an HRQoL measure for adults with
PCD (22). These instruments can be used to
document the progression of disease,
monitor patients clinically, and serve as an
outcome measure for clinical trials on the
impact of new therapies from the patient
perspective. In PCD, this is particularly
important given that there are few
physiologic end points that can be used for
these purposes.
The key principle governing all phases
of instrument development was our
inclusion of patient and parent input at each
phase. To ensure the generalizability and
validity of these measures, we developed
them cross-culturally in English-speaking
countries (Canada, the United States, the
United Kingdom, Ireland) and found few
differences in critical item content across
countries, despite using slightly different
methodology for questionnaire
development in North America and Europe.
All phases of instrument development
required by relevant regulatory bodies were
followed in North America and Europe.
Additional input was obtained from
published literature and medical experts in
these locations. These processes have
yielded reliable and valid HRQoL
instruments for a variety of chronic
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conditions, such as CF and bronchiectasis
(23, 24).
Open-ended and cognitive interviews
highlighted the importance of the impact of
respiratory and sinus symptoms on patients’
daily functioning. These symptoms were
similar to those reported by patients with
CF and bronchiectasis (12, 25) and
included chronic cough, mucus production,
trouble breathing, and sinus headaches.
However, several items that appear on the
final QOL-PCD measures reflect symptoms
and functioning that are unique to PCD,
such as runny nose, congestion in the nose,
chronic otitis media, difficulty hearing,
speech delays, and in some cases, a need for
special accommodations in the classroom.
These distinct symptoms are attributable
to the abnormal functioning of the cilia,
which disrupts normal mucus clearance
from the lungs, nose, sinuses, and middle
ear (1). In contrast, CF is characterized by
predominantly lower respiratory tract and
gastrointestinal symptoms, and ear disease
is not a feature of CF.
Furthermore, unlike individuals with CF,
patients with PCD did not endorse symptoms
related to body image, gastrointestinal
discomfort, or eating and weight problems.
Patients with PCD are pancreatic sufficient,
and although their appetite may decrease
when they are ill (i.e., during a pulmonary
exacerbation), they do not have the primary
nutritional and growth issues associated with
CF. Hence, this finding provides additional
support for the content validity of our
measures.
Importantly, this study demonstrated
differences in HRQoL based on respondent
age. Younger children did not mention
more abstract concepts, such as health
perceptions, vitality, and role functioning,
which is typical across disease-specific
patient-reported outcomes (22). In contrast,
adolescents reported that PCD affected
their energy levels and functioning at
school. These findings underscore the
Table 3. Saturation grids from open-ended interviews for North American and UK adolescents with primary ciliary dyskinesia: sinus
symptoms and treatment burden
Adolescents from North America and the UK
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Total
Sinus symptoms
Runny nose 1 1 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 17
Stuffy nose (congestion) 1 0 1 0 0 1 1 1 1 1 1 0 1 1 1 1 1 0 0 0 13
Sinus headache 1 0 1 1 1 1 1 1 0 0 0 0 0 1 1 1 0 0 0 0 10
Postnasal drip 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2
Facial pain 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 2
Sinus infection 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2
Sore throat 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 2
Treatment burden
Hard to fit in treatments 1 1 0 0 0 1 0 1 1 0 0 1 1 1 0 0 1 1 1 1 12
Prefer other activities to treatment 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 1 1 0 1 7
Treatments are bothersome 0 1 1 1 1 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 7
Don’t want to do treatments 0 0 1 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 7
Social barriers to treatment 1 0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 5
Difficulty remembering treatments 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 3
Don’t think treatments are necessary 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 3
Treatments affect social life and
other activities
1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 4
Note: Participant endorsement of row item indicated by “1.” Boldface “1” indicates first endorsement of item by any participant. Saturation was reached by
the end of the ninth interview for sinus symptoms and by the end of the third interview for treatment burden.
You had to stop having fun to do your treatments 
Always
Often
Sometimes
Never
Play Again
Question 11 of 37
QUESTIONNAIREQOL-PCD
And in the past week, click how often:
Figure 2. Image from the electronic children’s version of the QOL-PCD, illustrating the question
“During this past week, indicate how often you had to stop having fun to do your treatments.”
(Questionnaire printed with permissions, and image provided by Robert Scott.)
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importance of using developmentally
appropriate HRQoL instruments that
reflect the respondent’s cognitive and
developmental stage, and that will optimize
sensitivity and specificity (15, 23, 26). It is
also advantageous to have both child and
parent proxy versions of these measures for
younger children to facilitate comparisons
between parent–child dyads, and to identify
a fuller picture of the effects of PCD on
daily functioning, allowing us to evaluate
children’s HRQoL from the earliest possible
age (26).
Strengths and Limitations
A strength of this study was our success
in recruiting a large and geographically
disparate sample of patients with this rare
disease from North America and Europe.
These samples represented different ethnic
groups, including Pakistani and Irish
travelers (a European minority group).
However, because participants were
required to understand and speak English,
we likely oversampled white participants.
Although we did not have African
Americans in our samples, to date, PCD has
been described in only a few patients from
this race (17).
A limitation of our study is that we used
convenience sampling methods, but
importantly, we used a wide range of
recruiting strategies, including advertisements
in patient advocacy newsletters, national PCD
education days, and patients seen in clinic
settings. This enabled us to include a
sociodemographically diverse patient
population. In the next phase of instrument
development, national psychometric testing,
we will systematically evaluate the
generalizability of these instruments.
Summary
QOL-PCD measures have now been
developed using the most recent guidance
from the FDA and EMA, and have
undergone cognitive testing in pediatric
patients from several English-speaking
countries. Despite the rarity of this disease,
we used two key collaborative projects
(GDMCC [National Institutes of Health,
Bethesda, MD] and European Union
BESTCILIA) to recruit a substantial number
of patients with a confirmed diagnosis of
PCD.
These instruments have already been
translated into Dutch, German, Danish,
French, and Greek with plans to develop
additional translations for other NorthT
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American populations (Latin American
Spanish) and major countries in Europe
and the Middle East. A multinational,
psychometric field study is underway to
assess item and scale reliability, convergent
and divergent validity, and responsiveness.
These questionnaires are expected to be
useful as end points in clinical trials, for
monitoring health outcomes in prognostic
studies, for generating quality improvement
initiatives, and for improving clinical
decision-making. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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